IS Pharma goes for global growth

HOSPITAL medicine group IS Pharma said today it is well positioned for international growth as its strategy of building a late-stage pharmaceutical business is paying dividends.

Chester-based IS Pharma, which earlier this year changed its name from Maelor, said over the last five months its portfolio of critical care, neurology and oncology drugs has grown organically. It has also further developed its presence in the major international markets of the US and Canada.

In its AGM statement the group said: “With an earnings focus and a strong balance sheet, the company is well positioned for growth.”

IS Pharma added that the integration of Speciality European Pharma International, which it bought earlier this year, is progressing well and within budget. The acquisition boosted IS Pharma’s critical care portfolio and opened up new international markets for the company.

Last week, the group announced that it will receive a one-off payment of $1.25m in connection with the North American rights for its critical care drug, Haemopressin, which will result in its end of year results being ahead of expectations.